Acz885

Other Medications

Experimental

Not available 1 Clinical Trials

Description

Acz885 is an investigational drug being studied by Novartis Pharmaceuticals. It is currently in early-phase clinical trials (Phase 1) and is not yet approved for treating colorectal cancer (CRC) or any other condition. The trials involving Acz885 in CRC are part of broader studies exploring its potential use in combination with other investigational agents (like CJM112, EGF816, PDR001, TMT212) or other approved drugs. These early trials primarily focus on determining the safety and tolerability of Acz885, understanding how the body processes the drug (pharmacokinetics), and observing any effects on the body or the tumor (pharmacodynamics). The goal is to find the right dose and understand how Acz885 might work before moving to larger studies to test its effectiveness.

Mechanism of Action

The specific way Acz885 works (its mechanism of action) is still under investigation in clinical trials. It is being studied in combination with other drugs, suggesting it may target pathways involved in cancer growth or the body's response to cancer. The trials are designed to help researchers understand how Acz885 interacts with other agents and its potential impact on tumor cells or the tumor environment.

Side Effects

As Acz885 is an investigational drug in early-phase trials The full range of potential side effects is still being evaluated. Information from the Phase 1 trial (NCT02900664) involving Acz885 in combination with other agents in various cancers (including CRC) would provide more specific data on side effects. However Based on the early stage of development Side effects are still being carefully monitored and characterized in ongoing studies. Common side effects in early trials can vary widely depending on the dose and the specific combination used.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02900664 Phase 1

Archived

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

United States, Belgium, Canada, France, Israel, Italy, Singapore, Spain, Taiwan

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.